Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Restructuring (2010 - 2016)

Harvard Bioscience (HBIO) reported Cash from Restructuring of -$27000.0 for Q3 2016, down 80.0% year-over-year from -$135000.0 in Q4 2015, and down 350.0% on a QoQ basis from -$6000.0 in Q4 2015.

Harvard Bioscience (HBIO) has 6 years of Cash from Restructuring data on file, last reported at -$27000.0 in Q3 2016.

  • Quarterly Cash from Restructuring fell 80.0% year-over-year to -$27000.0 in Q3 2016, while the trailing twelve-month figure through Dec 2017 was -$27000.0 (changed 0.0% YoY) and the FY2016 annual result came in at -$27000.0, up 68.24% from the prior year.
  • Cash from Restructuring retreated to -$27000.0 in Q3 2016 per HBIO's latest filing, from -$6000.0 in the prior quarter.
  • Across five years, Cash from Restructuring topped out at $95000.0 in Q3 2013 and bottomed at -$102000.0 in Q1 2014.
  • The 4-year median for Cash from Restructuring is -$21000.0 (2013), against an average of -$25272.7.
  • The widest annual swing landed in 2014, when Cash from Restructuring soared 30.43%; it then slumped 650.0% in 2015.
  • Tracing HBIO's Cash from Restructuring over 4 years: stood at -$97000.0 in 2013, then jumped by 97.94% to -$2000.0 in 2014, then tumbled by 200.0% to -$6000.0 in 2015, then sank by 350.0% to -$27000.0 in 2016.
  • Per Business Quant, the three latest HBIO Cash from Restructuring figures stand at -$27000.0 (Q3 2016), -$6000.0 (Q4 2015), and -$15000.0 (Q3 2015).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2016 -27,000.00
Dec 31, 2015 -6,000.00
Sep 30, 2015 -15,000.00
Jun 30, 2015 -64,000.00
Sep 30, 2014 -2,000.00
Jun 30, 2014 -16,000.00
Mar 31, 2014 -102,000.00
Dec 31, 2013 -97,000.00
Sep 30, 2013 95,000.00
Jun 30, 2013 -23,000.00
Mar 31, 2013 -21,000.00
Dec 31, 2011 -70,000.00
Sep 30, 2011 308,000.00
Dec 31, 2010 79,000.00